Myovant Sciences EBITDA Margin 2017-2022 | MYOV

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Myovant Sciences (MYOV) over the last 10 years. The current EBITDA margin for Myovant Sciences as of March 31, 2022 is .
Myovant Sciences EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2022-03-31 $0.23B $-0.18B -79.22%
2021-12-31 $0.20B $-0.21B -106.06%
2021-09-30 $0.15B $-0.23B -157.93%
2021-03-31 $0.06B $-0.26B -437.29%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.033B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00